London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The funny thing this dropped a few ours ago on a rumour. It has not returned to where it is Yet then there was the other rumour of activity galore going on at primer . Nothing happened sp wise.
Theres has to be some really positive news to move this it seems . The company dont seem bothered at all. Well that means we must sit it out.
Rtest I take your point sometimes the strangest things can drive debate forward. Imho.
CS - Not at all. My investment strategy is subject of a rolling review. I now view both companies as medium/long term investments, but that wasn't the case when I invested in NCYT. Graham Mullis could not have made things clearer: 'a leading, global diagnostics business'. Diagnostic testing is not NCYT's 'core business', but it was NCYT's C-19 test which effectively made the company. And I am anticipating a positive impact on all areas of NCYT business going forward . My interest in the other company did not begin with a poc test, which remains under development. It began with the other treatment and therapies, particularly 'preCISION'. Cytiva , McNulty and I, appear to have reached the same conclusion!
CS Novacyt are planning releasing 3 new tests in June you are aware of these?
Exsig - 60 min test on their genesig® q32 unit
Current test on 384 well units (x4 throughout)
OptiGene LAMP test - 5>20 mins with Novacyt making primers
Wonder how many q16 and q32 units they have shifted
Captain you crack me up. I find you so amusing you are in another share that i am also in. But let me ask you a question will you still be in that one if the trials fail or you dont get approvals. Its very ambiguous to say the least.
But with ncyt they do have approvals they do have large orders they do have money in the bank
Why do you bother keep coming out with the same old statements week after week.
At this moment in time ncyt is out in front not saying it will stay there.
The most sensible thing you have said all day is that there is room for many at the table.
Its not a winner takes all scenario.
I am sure you will continue i hope you do because no one makes me laugh like you do. So heres to next weeks edition. Keep up the humour my friend your priceless.
I honestly have no idea why people are wasting their time responding to CS. I'm trying to work out why hes even writing on this BB in the first place it's pretty sad and pathetic and clearly has too much time on his hands. In responding you're just fueling him to respond with more incorrect nonsense and anti garbage. Just filter him or ignore and move on. Simple!
The link vanv was referring to.
A fantastic write up in the Times this weekend for #NCYT, followed by the CEO and Chair buying a combined £90k this AM on the open market.
For me, the shares remain extremely undervalued at 345p. I see it back above 500p in the next couple of weeks.
Wilson63 - thanks for posting the links. The journal the Guardian is referring to is poor. It is a systematic review and acknowledges that itself that it might not hold up to scrutiny by stating that it was put together in haste. Like you said also nothing about nyct
You nail your colours to two masts and then drop one when the other proves superior?
NCYT's PCR offering is the well established existing technology. Nothing fancy but does the job well enough.
This is a fast moving field though. Will it be enough in July, August or through 2021?
CS - NCYT does not have the capacity to become the 'monopoly player' in the C-19 diagnostic test market, but it does have a good enough test and the manufacturing capacity to produce and sell millions of these tests to transform the company, and this is what has happened. No matter how good a p.o.c. test is, there will be a need for a lab-based platform. It was Germany's robust and far reaching lab structure which saved the day there, limiting C-19 deaths to 8000.
Much has been made of Myles McNulty's contributions and research notes. In his latest note he deliberately side-stepped the competing interests of NCYT and the other company. Now visit his twitter page and have a look at his comments about NCYT on 18th May, following the article in 'The Times' by Alex Ralph. It will then become clear why he side-stepped this issue in his comprehensive note! Btw, you side-stepped my question! Why has Cytiva nailed its colours to two masts - PCR & POC?
Captain. Here's the article you haven't posted.
The following is a quote from the article.
Asked by Madders to name all the Covid-19 tests in use, Dorries declined to do so. She simply replied: “There are eight key testing platforms which deliver the majority of testing. All these tests are clinically validated and have high levels of performance.”
That's eight(8) testing platforms.
Now I'm not going to spend an hour digging out stuff however please do full research re most accurate pcr test before you state it is actually Novacyt.
You said taken incorrectly will result in this number. So if taken correctly the number will be less than 25%? If taken incorrectly you are saying 25% error? So that means automatically, even without anything else discussed the false rate is less than 25%, as many/most will be taken correctly.
What were the false positives verified against?
How many institutions was this study from?
A nice round number like a quarter/25%?
This doesn't sound like any verified study
CS, come back when you have a CE marked product with confirmed specificity and sensitivity, all you’re doing is speculating the AVCT test will be more accurate when you don’t currently have a product,
It's not NCYT specific but any nasopharyngeal swab taken incorrectly will result in about a 25% false negative.
That's what happened all last week and will happen all next week too.
It's just the way it is with nose/throat swabs I'm afraid.
But that's fine for NCYT because at the moment that's the only test there is.
My point is that should other tests come along in the next week or two.....
well then that would be different wouldn't it?
Can you point me to the 25% false negative report please?
I'm aware there are concerns with the samples being taken correctly but I haven't seen any report suggesting the test itself is problematic
Post link. Which nyct platform, how many institutions was this sampled from, was this in controlled laboratory conditions, what were the false negatives verified against?
And NCYT's reported 25% false negative problem Wbernard?
Or is that different somehow?
25% false negatives?!
Lawyers you say?
I do hope not for yours and NCYT's sake.
Any competitor has to come up with a test with higher sensitivity/specificity to stand a chance. The litigation risk for any company is too large to use an inferior test, if employers test employees or airlines test passengers and an inferior test is used and that individual comes back negative but is intact positive and infects others then proceedings will be brought.
Currently, nyct also has a relationship, equipment and training of testers advantage.
Ummm shall I sit on my hands and wait and see if numerous companies actually manage to succeed or shall I order what I can now ? Ncyt gold standard WHO approved. I wonder if the WHO with the billion tests they want will wait for several months so that they have a choice. Bet Boris isn't waiting either!
Wilson, it’s crazy he’s posted 53 times on our board and 61 on his own board. Why do I see an image of uncle Albert every time I see his name lol.
Anders_uk he's not posted on there for four days!! The Rns could just as well have the word exsig in it Now that would be a killer.
CS isn't invested here, he's just trying to sow seeds of doubt. AVCT now valued at £390 ????? without having sold a bean. All the arguments he used in his last post apply to them as well so where would that sp go ? He's a tool & should be treated like one.
Captain desperate salesman back again. Some of us don’t believe in your bubble stock, we’re happy investing in the gold standard PCR test and don’t want to risk investing in a new technology that may or may not work, or be delivered in time to make some actual sales.
Jog on back to your own board...
Captain Stanley - are you invested in here still?
I think we agree Van. No one will have a monopoly and it'll be competitive.
My point, such as it was, is that I feel NCYT is currently valued as the monopoly player. Because at the moment it pretty much is. But it's offering may well be very much second best within a month or two.
Today NCYT has premium value pricings and share price valuations but when someone else comes along with something better that premium will last until 0800 when the stock exchange opens.
That might be tomorrow morning? Or perhaps a week today?
I don't know when exactly but I do know that several companies may very well release such a 'killer' RNS within the next week or two. Want to be holding NCYT then?